A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations
NCT06585241
This study is recruiting at 6 US sites in 5 states, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this study is to investigate the immunogenicity and safety of mRNA COVID-19 variant-containing vaccine formulations against the vaccine-matched variants and newly emerged variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- SARS-CoV-2
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 4
- Ages
- 6 months and older
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- ModernaTX, Inc.
- Last updated on ClinicalTrials.gov
- March 27, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Georgia · 2
- CenExel · Atlanta, GA
- CenExel · Decatur, GA
Louisiana · 1
- Velocity Clinical Research · Baton Rouge, LA
Mississippi · 1
- Velocity Clinical Research · Gulfport, MS
Nebraska · 1
- Velocity Clinical Research · Omaha, NE
Virginia · 1
- Richard Bennett - Clinical Research Partners · Richmond, VA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.